PCRX · Pacira BioSciences
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $40.11
Note written ·
Price against the kill line
9.1% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $40.11, on record since 11 November 2026. The shares are up 56.9% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $40.11, well over the $36.50 offer price, which would show the market pricing a higher bid and the shares leading the S&P 500; Viatris raising its offer or a rival bidder making a superior proposal would also prove this call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 177
- Revenue, change on a year (%)
- −1.6
- Gross margin (%)
- 78.9
- Operating margin (%)
- 12.6
- Free cash flow, four quarters ($M)
- 169
- Net cash, cash less debt ($M)
- 2.0
- Price to earnings (×)
- 38.7
- Enterprise value to sales (×)
- 2.0
All filed numbers
What Pacira BioSciences reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 177 | −1.6 | 78.9 | 12.6 |
| first filed | 192 | +6.2 | 77.0 | 2.2 |
| first filed | 177 | +5.0 | 79.5 | 3.9 |
| first filed | 197 | +5.1 | 79.5 | 1.2 |
| first filed | 180 | +6.5 | 80.9 | 3.5 |
| first filed | 181 | +1.7 | 77.4 | 4.7 |
| Pre-tax income ($M) | 28.8 |
| Net income ($M) four quarters: 37.7 | 28.5 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | −8.2 |
| Operating cash flow ($M) | 177 |
| Capital spending ($M) | 7.9 |
| Free cash flow ($M) | 169 |
| Cash and short-term investments ($M) | 296 |
| Debt ($M) long-term debt | 294 |
| Net cash, cash less debt ($M) | 2.0 |
| Deferred revenue ($M) | 2.0 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 123 |
| Inventory ($M) | 130 |
| Shareholders' equity ($M) | 712 |
| Market value ($M) | 1,462 |
| Enterprise value, market value plus net debt ($M) | 1,460 |
| Enterprise value to sales (×) | 2.0 |
| Enterprise value to operating income (×) | 40.8 |
| Price to earnings (×) | 38.7 |
| Price to book value (×) | 2.1 |
| Free-cash-flow yield (%) | 11.6 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 10.6% of shares outstanding sold short, 1.1 days of average trading to cover, −47.2% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $218K |
| 12 monthsfrom | $0 | $2.5M |
The thesis
Pacira BioSciences trades as a takeover with a fixed price. Viatris is paying $36.50 per share in cash, and the shares closed at $36.46 on 11 November 2026, so they are more likely to lag the S&P 500 than to lead it. The tender offer expiring at 11:59 p.m. Eastern on 16 November 2026 decides whether the cash is paid.
Viatris announced the deal on 8 October 2026, valuing Pacira's equity at $1.65 billion, according to its 8-K. It started the tender offer on 30 October 2026. One of the two main conditions is already met: the Hart-Scott-Rodino (HSR) antitrust waiting period expired just before midnight on 29 October 2026, MLex reported on 30 October 2026. The main condition left is that more than 50% of outstanding shares are tendered.
The index provider is already planning for the deal to close. S&P Dow Jones Indices said on 11 November 2026 that Ingram Micro will replace Pacira in the S&P SmallCap 600 before the open on 17 November 2026. With HSR cleared and the shares a few cents under the offer, the rating is Low. The remaining upside is the small gap to $36.50, and a higher price would need a rival bidder or a raised offer.
Bullish and bearish views on Pacira BioSciences, Inc.
The bull case on Pacira BioSciences, Inc. (PCRX), in brief: the antitrust condition is already met. The bear case: the offer price caps the upside.
Bull case
- The antitrust condition is already met. The HSR waiting period expired on 29 October 2026, MLex reported on 30 October 2026. That removes the condition most likely to delay a healthcare deal.
- The deal has no financing condition. Viatris said on 8 October 2026 it will pay mainly from excess cash, with the rest from short-term borrowings.
- The second step needs no shareholder vote. The merger follows the tender under Delaware Section 251(h). Holders who do not tender receive the same $36.50 in cash, per Investing.com's 30 October 2026 report on the offer terms.
- Pacira's board recommends tendering. The board approved the deal unanimously, according to coverage of the 30 October 2026 tender launch.
Bear case
- The offer price caps the upside. The shares closed between $36.40 and $36.49 in every session from 4 November to 11 November 2026, all below the $36.50 offer. RBC raised its target to exactly $36.50 on 10 November 2026.
- The standalone business is shrinking slightly. Third-quarter 2026 revenue was $176.65 million against $179.52 million a year earlier, according to the 10-Q filed on 5 November 2026. Diluted earnings per share were $0.70.
- There is no standalone outlook to fall back on. Pacira withdrew its 2026 guidance on 5 November 2026 because of the pending merger, Benzinga reported.
- A failed deal would remove the takeover premium. The shares jumped 44.0% to $36.3 in the 8 October 2026 session when the deal was announced, Benzinga reported. The 52-week closing low was $19.16 on 16 January 2026.
- Some conditions are still open. Besides the minimum tender, the offer requires no legal restraint and no material adverse effect at Pacira, according to a 2 November 2026 New Moon Special Situations summary of the offer terms.
Price setup
The shares closed at $36.46 on 11 November 2026, close to the 52-week intraday high of $36.66 set on 15 October 2026. They are up 57.3% over three months from $23.18 on 13 August 2026, and nearly all of that came in the 8 October 2026 session. On adjusted daily closes, the 50-day moving average is $30.79 and the 200-day is $25.49 as of 11 November 2026. Both still include months of trading from before the deal.
Since the launch, the shares have traded like a merger-arbitrage position, holding within cents of the offer. On 30 October 2026 the gap to $36.50 was $0.11, about 0.30%, New Moon Special Situations calculated. A close well below the post-announcement range would be the first sign that the market doubts the tender will close.
Insiders have not bought. SEC Form 4 filings show Senior Vice President of Finance Lauren Riker sold 6,000 shares at $36.32 on 8 October 2026 under a Rule 10b5-1 plan after exercising options at $32.35. Chief Financial Officer Shawn Cross had 9,540 shares withheld for tax at $36.39 on 30 October 2026.
Catalysts ahead
- 16 November 2026: Viatris tender offer for Pacira expires at 11:59 p.m. ET. If more than 50% of outstanding shares are tendered and the offer is not extended, the $36.50 cash price is paid and the shares stop trading on their own. An extension would signal an unmet condition.
- 17 November 2026: Ingram Micro replaces Pacira in the S&P SmallCap 600 before the open. The index change assumes the deal closes on schedule. If the tender is extended, the timing of the index change would show the delay.
- ~17 November 2026 (est.): Expected acceptance of tendered shares and payment. Acceptance completes the acquisition in practice, and the Section 251(h) merger then converts untendered shares to $36.50 cash.
- 8 April 2027: Merger agreement outside date. This matters only if the tender is still open. A deal running this long would mean a condition has failed, and the takeover premium would be at risk.
What would change the view
A daily close above $40.11, well over the $36.50 offer price, which would show the market pricing a higher bid and the shares leading the S&P 500; Viatris raising its offer or a rival bidder making a superior proposal would also prove this call wrong.
What it trades with
Until the deal closes, the shares track the $36.50 offer. They have little sensitivity to the S&P 500, to biotech indices or to Pacira's own quarterly sales. Over three months, they could beat the index mainly if the index falls, or if a higher bid appears.
If the tender completes on schedule, the shares stop trading on their own and are replaced in the S&P SmallCap 600 before the open on 17 November 2026, per S&P Dow Jones Indices. Viatris (VTRS) carries the same deal from the buyer's side. Its shares carry the integration and borrowing risk, while the cash price for Pacira holders is fixed.
The evidence, claim by claim (8)
- Viatris agreed to acquire Pacira for $36.50 per share in cash, an aggregate equity value of $1.65 billion. Viatris 8-K and press release, Exhibit 99.1 · as of
- Viatris subsidiary Peach Purchaser Sub commenced the $36.50 cash tender offer; it expires at 11:59 p.m. ET on 16 November 2026 unless extended or terminated. Investing.com report on the tender launch · as of
- The Hart-Scott-Rodino waiting period for the Viatris-Pacira deal expired just before midnight on 29 October 2026. MLex, 30 October 2026 · as of
- Third-quarter 2026 revenue was $176.65 million against $179.52 million in the same quarter of 2025; diluted EPS was $0.70. Pacira 10-Q for the period ended 30 September 2026; Q3 2026 results release · as of
- Pacira withdrew its 2026 financial guidance pending the proposed merger with Viatris. Benzinga report, 5 November 2026 · as of
- RBC Capital raised its Pacira price target to $36.50, equal to the offer price. RBC Capital note reported 10 November 2026 · as of
- Ingram Micro will replace Pacira BioSciences in the S&P SmallCap 600 effective prior to the open on 17 November 2026. S&P Dow Jones Indices announcement, 11 November 2026 · as of
- SVP Finance Lauren Riker exercised 6,000 options at $32.35 and sold 6,000 shares at $36.32 on 8 October 2026 under a Rule 10b5-1 plan. SEC Form 4 filed 9 October 2026 · as of
Sources
- Viatris, Pacira cleared HSR waiting period on Oct. 29 · mlex.com ·
- Pacira (PCRX): $36.50 cash, with only a 0.30% dated gap · newmoonspecialsituations.substack.com ·
- Viatris launches tender offer for Pacira at $36.50 per share · investing.com
- Viatris Inc - Form 8-K - FY2026 · sec.gov
Related · shared themes
GPN
Global Payments
Global Payments trades on a reported $40 billion CD&R and GTCR buyout, and nine brokers raised targets after in-line third-quarter results…
ADT
ADT
ADT Inc. trades as a pending $10.00-per-share cash buyout by Thrive Holdings, so its shares are more likely to lag the S&P 500 than lead…
BMBL
Bumble
Bumble's shares are likely to trail the S&P 500 because they trade as a pending $6.05-per-share cash takeover by Ithaca Holdings, closing…
BRZE
Braze
Salesforce's agreed $47.50-per-share cash takeover of Braze caps the shares just under the offer, so they are more likely to lag the S&P…